CYP3A5*3A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia (2008)
- Authors:
- Willrich, Maria Alice Vieira
- Hirata, Mario Hiroyuki
- Genvigir, Fabiana Dalla Vecchia
- Arazi, Simone Sorkin
- Rebecchi, Ivanise Marina Moretti
- Rodrigues, Alice Cristina
- Bernik, Marcia Martins Silveira
- Dórea, Egidio Lima
- Bertolami, Marcelo Chiara - Instituto Dante Pazzanese de Cardiologia (IDPC)
- Faludi, André Arpad - Instituto Dante Pazzanese de Cardiologia (IDPC)
- Hirata, Rosario Dominguez Crespo
- USP affiliated authors: HIRATA, MARIO HIROYUKI - FCF ; DOREA, EGIDIO LIMA - HU ; HIRATA, ROSARIO DOMINGUEZ CRESPO - FCF
- Unidades: FCF; HU
- DOI: 10.1016/j.cca.2008.07.032
- Subjects: HIPERCOLESTEROLEMIA; POLIMORFISMO
- Language: Inglês
- Imprenta:
- Source:
- Título: Clinica Chimica Acta
- ISSN: 0009-8981
- Volume/Número/Paginação/Ano: v. 398, n. 1-2, p. 15-20, 2008
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
WILLRICH, Maria Alice Vieira et al. CYP3A5*3A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia. Clinica Chimica Acta, v. 398, n. 1-2, p. 15-20, 2008Tradução . . Disponível em: https://doi.org/10.1016/j.cca.2008.07.032. Acesso em: 03 mar. 2026. -
APA
Willrich, M. A. V., Hirata, M. H., Genvigir, F. D. V., Arazi, S. S., Rebecchi, I. M. M., Rodrigues, A. C., et al. (2008). CYP3A5*3A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia. Clinica Chimica Acta, 398( 1-2), 15-20. doi:10.1016/j.cca.2008.07.032 -
NLM
Willrich MAV, Hirata MH, Genvigir FDV, Arazi SS, Rebecchi IMM, Rodrigues AC, Bernik MMS, Dórea EL, Bertolami MC, Faludi AA, Hirata RDC. CYP3A5*3A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia [Internet]. Clinica Chimica Acta. 2008 ; 398( 1-2): 15-20.[citado 2026 mar. 03 ] Available from: https://doi.org/10.1016/j.cca.2008.07.032 -
Vancouver
Willrich MAV, Hirata MH, Genvigir FDV, Arazi SS, Rebecchi IMM, Rodrigues AC, Bernik MMS, Dórea EL, Bertolami MC, Faludi AA, Hirata RDC. CYP3A5*3A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia [Internet]. Clinica Chimica Acta. 2008 ; 398( 1-2): 15-20.[citado 2026 mar. 03 ] Available from: https://doi.org/10.1016/j.cca.2008.07.032 - Leptin receptor gene polymorphisms are associated with adiposity and metabolic alterations in Brazilian individuals
- Relationships among CYP3A4 and CYP3A5 haplotypes, mRNA expression, CYP3A activity and atorvastatin response in hypercholesterolemic individuals
- Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression
- The contribution of genetic polymorphisms in 60 candidate genes to variability in atorvastatin response
- Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients
- Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response
- Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression
- Differentiation of african components of ancestry to stratify groups in a case-control study of a brazilian urban population
- Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin
- CYP3A4 and CYP3A5 mRNA expression in hypercholesterolemic individuals under hypolipemiant therapy
Informações sobre o DOI: 10.1016/j.cca.2008.07.032 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
